TABLE 2.

Baseline demographic and clinical characteristics in the intervention study.

	Treatment group	Control group	t/z	P
N	18	21
Age (years)	81.8 ± 4.4	82.7 ± 5.5	−0.5	0.6
Education (years)	5.3 ± 4.2	6.5 ± 5.9	−0.7	0.5
Gender (female)	13(72.2%)	18(85.7%)	1.0	0.4
Serum TBIL (μmol/L)	10.5 ± 3.7	11.0 ± 4.0	−0.4	0.6
Serum DBIL (μmol/L)	4.2 ± 1.6	3.9 ± 1.4	−0.5	0.5
Serum IBIL (μmol/L)	6.2 ± 2.5	7.0 ± 3.2	−0.2	0.7
IBIL/ALB	0.167 ± 0.061	0.203 ± 0.125	−0.1	0.8
Serum TP (g/L)	72.8 ± 6.1	73.0 ± 4.2	−0.1	0.8
Serum ALB (g/L)	36.2 ± 5.0	38.1 ± 8.2	−0.8	0.4
MMSE scores	17.3 ± 5.0	18.1 ± 4.9	−0.2	0.7
ADAS-cog scores	24.9 ± 11.6	22.5 ± 10.8	0.6	0.5
ADCS-ADL scores	47.1 ± 20.0	56.2 ± 14.0	−1.6	0.1
NPI scores	10.5 ± 14.8	6.1 ± 8.8	−1.1	0.2
CDR-SB scores	6.1 ± 4.0	3.7 ± 2.8	−1.5	0.1

Data are presented as mean ± SD. TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; MMSE, Mini-Mental State Examination; ADAS-cog, Alzheimer’s Disease Assessment Scale—Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Co-operative Study—Activities of Daily Living; NPI, Neuropsychiatric Inventory; CDR-SB, Clinical Dementia Rating Scale—Sum of Boxes.